(S)-Warfarin | CAS#5543-57-7

MedKoo Cat#: 525731 | Name: (S)-Warfarin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(S)-Warfarin is a more potent enantiomer of Warfarin as a vitamin K antagonist, anticoagulant.

Chemical Structure

(S)-Warfarin

CAS#5543-57-7

Theoretical Analysis

MedKoo Cat#: 525731

Name: (S)-Warfarin

CAS#: 5543-57-7

Chemical Formula: C19H16O4

Exact Mass: 308.1049

Molecular Weight: 308.33

Elemental Analysis: C, 74.01; H, 5.23; O, 20.76

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 375.00
10mg	USD 650.00
25mg	USD 1,300.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

(S)-Warfarin

IUPAC/Chemical Name

4-Hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]chromen-2-one

InChi Key

PJVWKTKQMONHTI-HNNXBMFYSA-N

InChi Code

InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3/t15-/m0/s1

SMILES Code

O=C1C([C@H](C2=CC=CC=C2)CC(C)=O)=C(O)C3=C(O1)C=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 308.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yu J, Rioux N, Gardner I, Owens K, Ragueneau-Majlessi I. Metabolite Measurement in Index Substrate Drug Interaction Studies: A Review of the Literature and Recent New Drug Application Reviews. Metabolites. 2024 Sep 26;14(10):522. doi: 10.3390/metabo14100522. PMID: 39452902; PMCID: PMC11509402. 2: Jin S, Paludetto MN, Kurkela M, Kahma H, Neuvonen M, Xiang X, Cai W, Backman JT. In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants. Eur J Pharm Sci. 2024 Aug 30;203:106884. doi: 10.1016/j.ejps.2024.106884. Epub ahead of print. PMID: 39218046. 3: Agachi S, Beloukhova M, Mould D, Lemak M, Grishin S, Samsonov M. Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2024 Jul 10. doi: 10.1111/bcp.16175. Epub ahead of print. PMID: 38984761. 4: Chanteux H, MacPherson M, Kramer H, Otoul C, Okagaki T, Rospo C, De Bruyn S, Watling M, Bani M, Sciberras D. Overview of preclinical and clinical studies investigating pharmacokinetics and drug-drug interactions of padsevonil. Expert Opin Drug Metab Toxicol. 2024 Aug;20(8):841-855. doi: 10.1080/17425255.2024.2373108. Epub 2024 Jul 9. PMID: 38932723. 5: AlSaeed MJ, Ramdhan P, Malave JG, Eljilany I, Langaee T, McDonough CW, Seabra G, Li C, Cavallari LH. Assessing the Performance of In silico Tools and Molecular Dynamics Simulations for Predicting Pharmacogenetic Variant Impact. Clin Pharmacol Ther. 2024 Oct;116(4):1082-1089. doi: 10.1002/cpt.3348. Epub 2024 Jun 18. PMID: 38894625. 6: Parikh SJ, Edara S, Deodhar S, Singh AK, Maekawa K, Zhang Q, Glass KC, Shah MB. Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan. J Inorg Biochem. 2024 Sep;258:112622. doi: 10.1016/j.jinorgbio.2024.112622. Epub 2024 May 31. PMID: 38852293; PMCID: PMC11285081. 7: Willemin ME, Wang Lin SX, De Zwart L, Wu LS, Miao X, Verona R, Banerjee A, Liu B, Kobos R, Qi M, Ouellet D, Goldberg JD, Girgis S. Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab. CPT Pharmacometrics Syst Pharmacol. 2024 Jul;13(7):1117-1129. doi: 10.1002/psp4.13144. Epub 2024 Jun 3. PMID: 38831634; PMCID: PMC11247108. 8: Zayed AL, Hadieh M, Al Hroot J, Hameedat F, Jaber SA. Development of a rapid HPLC-fluorescence method for monitoring warfarin metabolites formation: In vitro studies for evaluating the effect of piperine on warfarin metabolism and plasma coagulation. Heliyon. 2024 May 14;10(10):e31266. doi: 10.1016/j.heliyon.2024.e31266. PMID: 38807873; PMCID: PMC11130653. 9: Putriana NA, Rusdiana T, Rostinawati T, Nurfuadah I. Validation of R/S-Warfarin Analysis Method in Human Blood Plasma Using HPLC with Fluorescence Detection and its Application to Patient Samples. J Pharm Bioallied Sci. 2024 Jan-Mar;16(1):44-50. doi: 10.4103/jpbs.jpbs_563_22. Epub 2024 Mar 21. PMID: 38694966; PMCID: PMC11060620. 10: Favaedi M, Pasebani Y, Kabiri A, Rafati A, Jalali S, Kiani A, Ahmadi R, Shadmehr A, Amirmazloomi A, Khajali Z. A Case of Unexplained Warfarin Resistance: A Case Report and Literature Review. J Tehran Heart Cent. 2023 Oct;18(4):302-306. doi: 10.18502/jthc.v18i4.14831. PMID: 38680643; PMCID: PMC11053237. 11: Geng K, Shen C, Wang X, Wang X, Shao W, Wang W, Chen T, Sun H, Xie H. A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole. CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):853-869. doi: 10.1002/psp4.13123. Epub 2024 Mar 15. PMID: 38487942; PMCID: PMC11098157. 12: Zenklusen I, Dingemanse J, Reh C, Gehin M, Kaufmann P. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs R D. 2024 Mar;24(1):97-108. doi: 10.1007/s40268-024-00456-8. Epub 2024 Mar 13. PMID: 38472696; PMCID: PMC11035509. 13: Liu Y, Sun J, Yang C, Qin M, Xu S, Zhao Y, Liu G. Safflower yellow for injection enhances anti-coagulation of warfarin in rats: implications in pharmacodynamics and pharmacokinetics. Xenobiotica. 2024 Feb;54(2):75-82. doi: 10.1080/00498254.2024.2326987. Epub 2024 Mar 13. PMID: 38445636. 14: Zhao Y, Yang C, Liu Y, Qin M, Sun J, Liu G. Effects of sodium ferulate for injection on anticoagulation of warfarin in rats in vivo. BMC Complement Med Ther. 2024 Feb 14;24(1):87. doi: 10.1186/s12906-024-04389-2. PMID: 38355450; PMCID: PMC10865636. 15: Uno Y, Minami Y, Tsukiyama-Kohara K, Murayama N, Yamazaki H. Identification of cytochrome P450 2C18 and 2C76 in tree shrews: P450 2C18 effectively oxidizes typical human P450 2C9/2C19 chiral substrates warfarin and omeprazole with less stereoselectivity. Biochem Pharmacol. 2024 Oct;228:115990. doi: 10.1016/j.bcp.2023.115990. Epub 2023 Dec 16. PMID: 38110158. 16: Çatıkkaş B, Karacan N. Molecular Docking and Dynamics Simulations of Ammi visnaga L. Constituents as Antimelanogenic, Anti-Inflammatory and Anticoagulant Agents. Chem Biodivers. 2023 Nov;20(11):e202301184. doi: 10.1002/cbdv.202301184. Epub 2023 Oct 18. PMID: 37850550. 17: Saad M, Zhang R, Cucchiarini A, Mehawej C, Mergny JL, Mroueh M, Faour WH. G-quadruplex forming sequences in the genes coding for cytochrome P450 enzymes and their potential roles in drug metabolism. Biochimie. 2023 Nov;214(Pt A):45-56. doi: 10.1016/j.biochi.2023.08.014. Epub 2023 Sep 1. PMID: 37660977. 18: Xue L, Singla RK, Qin Q, Ding Y, Liu L, Ding X, Qu W, Huang C, Shen Z, Shen B, Miao L. Exploring the complex relationship between vitamin K, gut microbiota, and warfarin variability in cardiac surgery patients. Int J Surg. 2023 Dec 1;109(12):3861-3871. doi: 10.1097/JS9.0000000000000673. PMID: 37598356; PMCID: PMC10720796. 19: Fu M, Luo L, Feng S, Lin H, Lu Z, Gu F, Fan Y, Wu B, Huang J, Shen K. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis. Br J Clin Pharmacol. 2023 Dec;89(12):3659-3668. doi: 10.1111/bcp.15856. Epub 2023 Aug 22. PMID: 37464978. 20: Kato T, Kunimoto Y, Kitagawa M, Asai Y, Kimyo T, Nakata H, Takahashi M, Chiba H, Takahashi H, Miyamoto A, Fukudo M. Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report. J Pharm Health Care Sci. 2023 May 1;9(1):14. doi: 10.1186/s40780-023-00282-1. PMID: 37122027; PMCID: PMC10150460.